Discovering drugs that target the DNA regulome
Company is active
Event Year: 2021
Company is active
Event Year: 2021
Talus Bio is pioneering a novel drug discovery platform focused on targeting previously inaccessible genome regulators, collectively known as the "regulome." Their innovative approach shifts drug discovery from artificial, often ineffective, systems back into the environment of live human cells, where regulome proteins can function naturally. By integrating automated cell processing, next-generation proteomics, and advanced data analytics, Talus Bio's technology enables comprehensive measurement of a drug's impact on the entire regulome within a single experiment, accelerating the development of new therapeutics.
Talus Bio is pioneering a novel drug discovery platform focused on targeting previously inaccessible genome regulators, collectively known as the "regulome." Their innovative approach shifts drug discovery from artificial, often ineffective, systems back into the environment of live human cells, where regulome proteins can function naturally. By integrating automated cell processing, next-generation proteomics, and advanced data analytics, Talus Bio's technology enables comprehensive measurement of a drug's impact on the entire regulome within a single experiment, accelerating the development of new therapeutics.
Total Raised: Unknown (Y Combinator backed)
Last Round: Summer 2021
Total Raised: Unknown (Y Combinator backed)
Last Round: Summer 2021
Healthcare
Healthcare
Healthcare -> Drug Discovery and Delivery
Healthcare -> Drug Discovery and Delivery
Team size: 16
Hiring: No
Team size: 16
Hiring: No